Now Enrolling: Study of Pegcetacoplan in Young People and Adults with C3G or MPGN

Apellis Pharmaceuticals has initiated the VALIANT study, a global Phase 3 clinical trial evaluating an investigational medication called pegcetacoplan (peg-set-a-koé-plan) for young people and adults with a diagnosis of C3G or MPGN*.

To be eligible for the study, participants must:

  • Be at least 12 years old
  • Be diagnosed with C3G or MPGN.
  • Have significant proteinuria (protein in the urine) confirmed by urine collections during the screening process
  • Have normal to moderately impaired kidney function, confirmed during the screening process
  • Weigh 30kg to 100kg
  • Be willing to use contraception during and for a period after the study

Additional criteria will be assessed at the research site to confirm eligibility.

 Pegcetacoplan is an investigational, targeted C3-inhibitor.  Investigational means that pegcetacoplan is not approved by any health authority for the treatment of C3G or MPGN. Talk to your doctor if you are interested in a clinical trial.

For more information, and to connect with a participating clinical trial site, email or visit

*C3G – Complement 3 glomerulopathy; MPGN (or IC-MPGN) – immune-complex membranoproliferative glomerulonephritis


Get the latest

For up-to-date news and information visit our news or join our mailing list below:

Join us, it's free!

Upcoming events

View upcoming events and dates in our MPGN/DDD Support Group calendar.

View Calendar


Find out what we’re doing right now and how you can help:

Read more